On a corporate action affecting ordinary shares of Karuna Therapeutics, Inc. (KRTX)

On December 22, 2023, Karuna Therapeutics, Inc. signed a merger agreement with Bristol-Myers Squibb Company under which Bristol-Myers Squibb Company will acquire Karuna Therapeutics, Inc. Karuna stockholders will receive $330 in cash per share of Karuna Therapeutics, Inc. that they own. The merger is anticipated to close in the first half of 2024. For more details, please, refer to the company’s website.

ITS Ltd. will publish separate notices on the procedures undertaken by ITS Ltd. to process this corporate action outlining how trading in these qualified investments will be carried out.